OncoMatch/Clinical Trials/NCT06902246
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
Is NCT06902246 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Regorafenib for unresectable hepatocellular carcinoma.
Treatment: Regorafenib — The purpose of this study is to determine the effects that Regorafenib in combination with Yttrium-90 (Y-90) radioembolization has on patients with unresectable hepatocellular carcinoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Hepatocellular Carcinoma
Prior therapy
Cannot have received: radioembolization
Prior radioembolization
Lab requirements
Blood counts
Platelet count > 100,000/mm3; hemoglobin (Hb) 9 g/dL; ANC 1,500/mm3
Kidney function
Serum creatinine ≤ 1.5 x ULN
Liver function
Child-Pugh A-B7; Serum bilirubin < 1.5 ULN; AST and ALT < 5 x ULN
Cardiac function
No active or clinically significant cardiac disease including: congestive heart failure (NYHA > Class II), active coronary artery disease, cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin, unstable angina, new-onset angina within 3 months, or myocardial infarction within 6 months
Child-Pugh A-B7. Serum bilirubin < 1.5 ULN; AST and ALT < 5 x ULN. Serum creatinine ≤ 1.5 x ULN. Platelet count > 100,000/mm3, hemoglobin (Hb) 9 g/dL, and absolute neutrophil count (ANC) 1,500/mm3. Active or clinically significant cardiac disease [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Miami · Miami, Florida
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06902246 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages